EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biodesix's enterprise value is $194.97 Mil.
Biodesix's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $49.09 Mil. Therefore, Biodesix's EV-to-Revenue for today is 3.97.
The historical rank and industry rank for Biodesix's EV-to-Revenue or its related term are showing as below:
BDSX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.51 Med: 3.09 Max: 19.5
Current: 3.97
During the past 6 years, the highest EV-to-Revenue of Biodesix was 19.50. The lowest was 0.51. And the median was 3.09.
BDSX's EV-to-Revenue is ranked worse than 58.67% of 225
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.04
vs BDSX: 3.97
As of today (2024-05-06), Biodesix's stock price is $1.40.
Biodesix's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.60. Therefore, Biodesix's PS Ratio for today is 2.35.
Biodesix EV-to-Revenue Historical Data
The historical data trend for Biodesix's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biodesix's EV-to-Revenue
For the Diagnostics & Research subindustry, Biodesix's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodesix's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Biodesix's EV-to-Revenue falls into.
Biodesix's current Enterprise Value is $194.97 Mil.
Biodesix's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $49.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodesix's share price for today is $1.40.
Biodesix's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.60.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodesix EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Biodesix's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BDSX has been successfully added to your 